[{"id":"c80eeae2-933f-4349-b377-8932b9e3ffc9","acronym":"rQNestin","url":"https://clinicaltrials.gov/study/NCT03152318","created_at":"2022-10-22T19:05:45.181Z","updated_at":"2024-07-02T16:35:40.606Z","phase":"Phase 1","brief_title":"A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","source_id_and_acronym":"NCT03152318 - rQNestin","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • linoserpaturev (CAN-3110)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/18/2017","start_date":" 07/18/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-08"}]